Nasdaq

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach

- ASGCT presentation demonstrates lipid nanoparticle (LNP) mediated delivery to the eye in the context of editing of the myocilin (MYOC) gene as a potential treatment for glaucoma - - Expands pipeline ...
Nasdaq

CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

ZUG, Switzerland and BOSTON, April 22, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

Crispr Therapeutics: Casgevy's Pediatric Win A Trigger For Bullish Sentiment

CRISPR Therapeutics wins FDA pediatric approval for Casgevy, boosting market potential and pipeline upside despite slow uptake. Click here to read more.
Labroots

CRISPR Virtual Event Series 2024

Labroots invites you to the 7th Annual Event in the CRISPR Virtual Event Series 2024 taking place on October 23rd, 2024! This event will continue the conversation of the abilities of CRISPR-based ...
Labroots

Keynote Presentation: Customized CRISPR-based technologies to treat human diseases w/ Live Q&A

Dr. Alves’s group is developing next-generation CRISPR-based genetic medicines to treat severe medical conditions with a main focus on neurological and metabolic diseases. Unlike conventional ...